Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
08 June 2022 - 9:00PM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced management
will participate in a fireside chat at the Goldman Sachs 43rd
Annual Global Healthcare Conference on Wednesday, June
15, 2022, at 2:00 p.m. PT.
A live webcast of the fireside chat will be available on the
“Events & Presentations” page within the Investors section of
the Alector website at http://investors.alector.com. A replay
will be available on the Alector website for at least 90 days
following the event.
About AlectorAlector is a clinical-stage
biotechnology company pioneering immuno-neurology, a novel
therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a
root cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and target
genetically defined patient populations in frontotemporal dementia
and Alzheimer’s disease. This scientific approach is also the basis
for the company’s immuno-oncology programs. Alector is
headquartered in South San Francisco, California.
For additional information, please visit www.alector.com.
Contacts:
1AB (media)Dan Budwick973-271-6085dan@1abmedia.com
Argot Partners (investors)Eric Kasper/Carrie McKimArgot
Partners212.600.1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Apr 2023 to Apr 2024